全球芳香化酶缺乏症市场 – 行业趋势和 2029 年预测

市场分析和规模                              

芳香酶缺乏症的特征是激素失衡，由于雌激素水平低和睾酮水平高，性发育和成熟会受到干扰。遗传上为女性的婴儿（有两条 X 染色体）的生殖器通常无法明确区分女性或男性（称为性别不明）。他们的生殖器官通常正常，但患者在儿童时期可能会出现卵巢囊肿，并且在青少年时期乳房发育和月经可能会受到影响。睾丸微小或隐睾的男性很少在晚年才被发现。男性还可能患有性欲缺乏、精子生成不足、不育或骨质疏松。

Data Bridge Market Research 分析称，2021 年芳香酶缺乏症市场价值为 9045 万美元，预计到 2029 年将达到 1.0935 亿美元，在 2022 年至 2029 年的预测期内复合年增长率为 2.40%。除了市场价值、增长率、细分市场、地理覆盖范围、市场参与者和市场情景等市场洞察外，Data Bridge Market Research 团队策划的市场报告还包括深入的专家分析、患者流行病学、管道分析、定价分析和监管框架。

报告范围和市场细分

Market Definition

 Aromatase deficiency is an uncommon condition that affects the synthesis of estradiol, causing hirsutism in pregnant women, pseudohermaphroditism and virilization in women, and tall height, osteoporosis, and obesity in men. Female patients may be candidates for surgical genitalia modification depending on the degree of ambiguity, and ovarian cysts must be monitored. After puberty, daily estrogen treatment (0.625 mg/twice weekly increasing to daily) is required, which can be augmented with progesterone-like hormone and monthly gonadotrophin-releasing hormone antagonist therapies. Adult men should begin treatment as soon as possible after being diagnosed, with daily transdermal delivery of up to 50 g of estradiol for 6-9 months to complete skeletal development. Estradiol replacement may be lowered to 25 g per day after epiphyseal closure. Calcium, vitamin D, and physical activity should be included to a low-calorie diet. Symptomatic treatment is required for dyslipidemia, insulin resistance and glucose intolerance.

Aromatase Deficiency Market Dynamics

Drivers

• Rise in the number of cases of aromatase deficiency

The surging number of cases of aromatase deficiency is a major factor driving the market's growth rate during the forecast period of 2022-2029. Aromatase deficiency is a sexual development condition characterized by low estrogen levels and high testosterone leels. Because of excessive growth of long bones in the arms and legs, affected people are abnormally tall. The aberrant bone growth causes slower mineralization and bone thinning, which can result in bone fractures with little impact.

• Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of aromatase deficiency market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.

Furthermore, rising government initiatives to spread awareness and sedentary lifestyle of people will result in the expansion of aromatase deficiency market. Along with this, favourable reimbursement policies will enhance the growth rate of the market.

Opportunities

• Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the aromatase deficiency market growth.

Moreover, the market's growth is fueled by rising technological advancement in diagnostic methods and emerging new markets. These factors will provide beneficial opportunities for the aromatase deficiency market growth.

Restraints/Challenges

On the other hand, high cost associated with the treatment as well as diagnosis will obstruct the growth rate of market. The lack of healthcare infrastructure in developing economies and dearth of skilled professionals will challenge the aromatase deficiency market. Additionally, lack of awareness among people and unfavourable healthcare policies will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This aromatase deficiency market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the aromatase deficiency market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Aromatase deficiency market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Global Aromatase Deficiency Market Scope

芳香酶缺乏症市场根据诊断、治疗、给药途径、发病年龄、最终用户和分销渠道进行细分。这些细分市场之间的增长将帮助您分析行业中增长缓慢的细分市场，并为用户提供有价值的市场概览和市场洞察，帮助他们做出战略决策，确定核心市场应用。

诊断

• 体格检查
• 基因测序
• 基因检测
• 其他的

治疗

• 外科手术
• 雌激素替代
• 其他的

发病年龄

• 儿科
• 成年人
• 老年病学

给药途径

• 口服
• 肠外
• 其他的

最终用户

• 医院
• 专科诊所
• 家庭护理
• 其他的

分销渠道

• 医院药房
• 零售药店
• 网上药店
• 其他的

芳香化酶缺乏症市场区域分析/见解

对芳香酶缺乏症市场进行了分析，并按国家、诊断、治疗、给药途径、发病年龄、最终用户和分销渠道提供了市场规模见解和趋势。

芳香酶缺乏症市场报告涉及的国家包括北美洲的美国、加拿大和墨西哥、欧洲的德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、亚太地区 (APAC) 的中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区 (APAC) 的其他地区、沙特阿拉伯、阿联酋、南非、埃及、以色列、中东和非洲 (MEA) 的其他地区、南美洲的巴西、阿根廷和南美洲其他地区

北美在市场份额和市场收入方面占据芳香酶缺乏症市场的主导地位，并将在预测期内继续保持主导地位。这是因为芳香酶缺乏症的患病率不断上升，医疗支出不断增加将进一步推动该地区市场的增长率。此外，主要关键参与者的不断增加也将进一步推动该地区市场的增长率。

由于该地区医疗保健基础设施的发展，预计亚太地区将在 2022-2029 年预测期内实现增长。此外，政府举措的不断增加将进一步推动该地区市场的增长率。

报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。   

竞争格局和芳香化酶缺乏症市场份额分析

芳香酶缺乏症市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对芳香酶缺乏症市场的关注有关。

芳香酶缺乏症市场的一些主要参与者是：

• F. Hoffmann-La Roche Ltd.（瑞士）
• Mylan NV（美国）
• 赛诺菲（法国）
• 辉瑞公司（美国）
• 葛兰素史克公司 (英国)
• 诺华公司（瑞士）
• 拜耳公司（德国）
• 礼来公司 (美国)
• 默克公司（美国）
• 艾尔建（爱尔兰）
• 雅培（美国）
• 默克集团（德国）
• 诺和诺德公司（丹麦）
• 基因泰克公司（美国）
• 安进公司 (美国)
• Endo International plc（爱尔兰）
• 久光制药株式会社（日本）

SKU-68374